SG
AZN icon

StoneX Group’s AstraZeneca AZN Stock Holding History

StoneX Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,506
Closed -$278K – 937
2025
Q4 		$278K Buy
1,506
+184
+14% +$32.3K 0.01% 733
2025
Q3 		$203K Buy
+1,322
New +$200K 0.01% 821
2025
Q2 		– Sell
-1,523
Closed -$224K – 883
2025
Q1 		$224K Buy
+1,523
New +$220K 0.01% 736
2022
Q1 		– Sell
-1,900
Closed -$221K – 552
2021
Q4 		$221K Buy
+1,900
New +$224K 0.03% 491
2021
Q3 		– Sell
-17,503
Closed -$2.1M – 471
2021
Q2 		$2.1M Buy
+17,503
New +$1.92M 0.31% 64
2017
Q3 		– Sell
-16,275
Closed -$1.11M – 185
2017
Q2 		$1.11M Buy
16,275
+9,683
+147% +$632K 0.35% 99
2017
Q1 		$360K Sell
6,592
-227
-3% -$13.2K 0.81% 45
2016
Q4 		$373K Sell
6,819
-415
-6% -$23.6K 0.65% 60
2016
Q3 		$475K Buy
+7,234
New +$473K 1.06% 43

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

StoneX Group's AZN Position: Q1 2026 in Review

StoneX Group sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,506 shares — an estimated $278K sold.

StoneX Group first reported a position in AZN in Q3 2016 and held it in 9 quarters. The position peaked at $2.1M in Q2 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • StoneX Group reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • StoneX Group sold 1,506 AstraZeneca shares in Q1 2026, an estimated $278K.
  • StoneX Group first reported a position in AstraZeneca in Q3 2016 and held it in 9 quarters.
  • StoneX Group's AstraZeneca position peaked at $2.1M in Q2 2021.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.